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The consideration of multivariable analysis derived risk factors for post trans-
plant events in the evaluation of potential cardiac transplant recipients and
donors may serve to improve mortality and morbidity after cardiac transplan-
tation. However, the application of this information is elusive due to the dif-
ficulty of applying all identified recipient and donor related risk factors, ex-
pressed as dichotomous and continuous variables, in the assessment of the
risk of post transplant events for a single patient. The CTRD has reported
multivariable risk factor analyses in the hazard function domain for post car-
diac transplant events from all primary transplants from 30 transplant centers
with 4.5 year follow-up. Variables analyzed in theses reports included multi-
ple recipient and donor demographic information, recipient and donor mis-
match variables, pre-transplant recipient and donor clinical variables, hemo-
dynamic variables, surgical variables, initial immunosuppression variables,
and post transplant event variables. Specific risk factors for post transplant
events were identified and multivariable equations were derived and have
been published,
In order to facilitate the application of this information, a computer pro-
gram was developed to allow the calculation of the estimated time-related
risk of post transplant events including death, time to first infection, time
to first rejection, and number of rejections in the first year. One enters the
values for specified variables into the program. The program then calculates
(utilizing solutions to the multivariable equations) and then displays the time-
related actuarial and hazard function curves, with standard errors, for each
event in graphical and tabular formats. Patient data may be stored, and data
output may be printed. Different patients or clinical situations for the same
patient may be compared on screen, The program is written in Microsoft
C, version 6, and runs in PC-DOS, Computer requirements include 640 kb
RAM, VGA graphics, and a floating point processor, Summary: Utilizing this
software package, a clinician may compute and print an individual patient's
time related risk profiles for post transplant death, infection, and allograft re-
jection. This information may be used for pre-transplant recipient education
and selection, and donor-recipient matching prior to transplantation.
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While information is crucial to medical care, organizing clinical and financial
data into useful, accessible information is difficult. Since 1972 Emory Uni-
versity has approached this with a clinical database (CDB) which includes
all cardiac catheterizations, coronary angioplasties and cardiac surgical pro-
cedures. Clinical data have been transcribed onto forms and hand keyed.
Financial data from the hospital and the Emory Clinic have been loaded via
tape. While the CDB has been used for clinical research, increasingly there
are demands to manage cardiovascular medicine on a daily basis. The com-
puter system was a traditional system with a central processor and terminals,
some of which had access via modem. This model has proven unworkable
due to 1) limited access geographically, 2) difficult access for personnel not
familial with with sophisticated database management system tools, 3} in-
creased expectations of what computers should do because of exposure to
graphical user interfaces (GUls) on personal computers, 4) inabilityto extend
data collection into new areas via paper forms and 5) increased demands
for service as a daily management tool. Independently of this effort Emory
University has put into place an Enterprise network, In 1993 the CDB, on a
Unix server, was made available on the network. Access is now available via
any IBM PC or compatible or Macintosh on the network. Access for both
individual and group data is being continually upgraded and simplified us-
ing GUI approaches, Local databases in cardiothoracic surgery and cardiac
Distributing a Cardiology Database on an
Enterprise Network: Changing Paradigms in
Information Systems
with significant CAD based on non-invasive data. We trained the ANN by us-
ing non-invasive data from 276 consecutive patients who underwent cardiac
catheterization, Input data included age, sex, history, physical exam, cardiac
risk factors, exercise stress test data (with or without nuclear imaging), The
ANN was trained to recognize significant CAD, defined as > 50% obstruc-
tion of the left main or other major epicardial vessels, The ANN was then
applied to patients not used in training. Significant CAD was identified with
a positive predictive accuracy of 80%, and a negative predictive accuracy of
92%. In conclusion, ANN can exclude patients without significant CAD with
a high degree (92%) of confidence. This technique has the potential to limit
the use of costly invasive procedures,
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In the era of health care reform, third party health payors are using deci-
sion support systems to justify the use of costly invasive procedures. In
the field of cardiology, a technology that could predict significant coronary
artery disease (CAD) from non-invasive data would be helpful. Artificial neu-
ral networks (ANN) have the potential to recognize subtle patterns in data
and apply its training to a new set of data. We trained a personal computer-
based ANN, using back propagation of errors through 23 hidden neurons,
incorporating logistic transfer function, in a single layer, to identify patients
These differences persisted upon multivariate adjustment for smoking,
use of antihypertensive medication, diabetes mellitus, body mass index, al-
cohol intake, total cholesterol and HDL cholesterol.
Postmenopausal HRT is associated with fibrinogen levels that are com-
parable to those found in premenopausal women. These data suggest that
the protective effect of postmenopausal HRT may be mediated in part by
favorable alterations in the hemostatic system.
Otavio C.E. Gebara, Brian Walsh, Murray A, Mittleman, Louise Greenberg, Francine
K, Welty, Izabela Lipinska, Da-Li Feng, Frank Sacks, Geoffrey H. Tofler, Institute for
Prevention of Cardiovascular Disease, Deaconess Hospital, and Brigham and Women's
Hospital, Harvard Medical School, Boston, MA
Estrogen usage in postmenopausal women is associated with a decrease in
cardiovascular events, however the mechanism is not well characterized. Al-
though observational studies suggest that estrogen may act in part through
an improvement in fibrinolytic potential, this has not been established in
placebo-controlled trials before and after estrogen therapy.
We performed a randomized, double-blind, placebo-controlled crossover
trial of oral estradiol (Estrace®, 1 mg, 2 mg) in 20 postmenopausal women.
Samples for fibrinolytic activity (fibrin plate assay) and tissue type plasmino-
gen activator (t-PAj antigen were collected at baseline and after 3, 6 and
9 weeks of therapy. Elevated t-PA antigen levels are associated with in-
creased cardiovascular risk, A repeated measures analysis of variance was
performed. There were significant treatment effects on fibrinolytic activity
and t-PA antigen. Results are presented for basal and 9 week timepoints.
Fibrinolytic potential is increased by estrace therapy, as indicated by an
increase in fibrinolytic activity and a reduction in tPA antigen. The effect was
more marked with the 2 mg preparation.
Since increased fibrinolytic activity has been associated with reduced car-
diovascular risk, these data suggest that one mechanism of the risk reduc-
tion associated with estrogen therapy in postmenopausal women may be
via a reduction in thrombotic tendency,
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